These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 29336715)

  • 21. Dyserythropoiesis of myelodysplastic syndromes.
    Lefèvre C; Bondu S; Le Goff S; Kosmider O; Fontenay M
    Curr Opin Hematol; 2017 May; 24(3):191-197. PubMed ID: 28072603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
    Brierley CK; Steensma DP
    Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
    Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
    Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TARBP2 inhibits IRF7 activation by suppressing TRAF6-mediated K63-linked ubiquitination of IRF7.
    Ling T; Weng GX; Li J; Li C; Wang W; Cao L; Rao H; Ju C; Xu LG
    Mol Immunol; 2019 May; 109():116-125. PubMed ID: 30927622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes.
    Yip BH; Dolatshad H; Roy S; Pellagatti A; Boultwood J
    Curr Pharm Des; 2016; 22(16):2333-44. PubMed ID: 26916023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic targeting of RNA splicing in myelodysplasia.
    Kim YJ; Abdel-Wahab O
    Semin Hematol; 2017 Jul; 54(3):167-173. PubMed ID: 28958291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toxoplasma gondii GRA7-Induced TRAF6 Activation Contributes to Host Protective Immunity.
    Yang CS; Yuk JM; Lee YH; Jo EK
    Infect Immun; 2016 Jan; 84(1):339-50. PubMed ID: 26553469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The tyrosine kinase Syk differentially regulates Toll-like receptor signaling downstream of the adaptor molecules TRAF6 and TRAF3.
    Lin YC; Huang DY; Chu CL; Lin YL; Lin WW
    Sci Signal; 2013 Aug; 6(289):ra71. PubMed ID: 23962979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aberrant pre-mRNA splicing of a highly conserved cell cycle regulator, CDC25C, in myelodysplastic syndromes.
    Caudill JS; Porcher JC; Steensma DP
    Leuk Lymphoma; 2008 May; 49(5):989-93. PubMed ID: 18464119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies.
    Harada H; Harada Y
    Cancer Sci; 2015 Apr; 106(4):329-36. PubMed ID: 25611784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Deregulated splicing machinery in myelodysplastic syndromes].
    Ogawa S
    Rinsho Ketsueki; 2012 May; 53(5):493-6. PubMed ID: 22728550
    [No Abstract]   [Full Text] [Related]  

  • 34. Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo.
    Shirai CL; Ley JN; White BS; Kim S; Tibbitts J; Shao J; Ndonwi M; Wadugu B; Duncavage EJ; Okeyo-Owuor T; Liu T; Griffith M; McGrath S; Magrini V; Fulton RS; Fronick C; O'Laughlin M; Graubert TA; Walter MJ
    Cancer Cell; 2015 May; 27(5):631-43. PubMed ID: 25965570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of Host Innate Immune Response by Hepatitis C Virus via Induction of Autophagic Degradation of TRAF6.
    Chan ST; Lee J; Narula M; Ou JJ
    J Virol; 2016 Dec; 90(23):10928-10935. PubMed ID: 27681126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place.
    Shallis RM; Chokr N; Stahl M; Pine AB; Zeidan AM
    Expert Rev Hematol; 2018 Sep; 11(9):715-726. PubMed ID: 30024293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging biological therapies for the treatment of myelodysplastic syndromes.
    Zeidan AM; Stahl M; Komrokji R
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):283-300. PubMed ID: 27486848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inositol polyphosphate multikinase promotes Toll-like receptor-induced inflammation by stabilizing TRAF6.
    Kim E; Beon J; Lee S; Park SJ; Ahn H; Kim MG; Park JE; Kim W; Yuk JM; Kang SJ; Lee SH; Jo EK; Seong RH; Kim S
    Sci Adv; 2017 Apr; 3(4):e1602296. PubMed ID: 28439546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy.
    Gill H; Leung AY; Kwong YL
    Int J Mol Sci; 2016 Mar; 17(4):440. PubMed ID: 27023522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes.
    Sallman DA; Tanaka TN; List A; Bejar R
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):613-620. PubMed ID: 29025689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.